Celldex Therapeutics (NASDAQ:CLDX) Shares Down 5.5% - Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s share price fell 5.5% during mid-day trading on Monday . The stock traded as low as $20.06 and last traded at $20.10. 889,296 shares were traded during trading, a decline of 5% from the average session volume of 937,358 shares. The stock had previously closed at $21.26.

Wall Street Analysts Forecast Growth

CLDX has been the subject of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Celldex Therapeutics in a research report on Friday, June 13th. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective for the company. UBS Group dropped their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, The Goldman Sachs Group decreased their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $50.11.

Celldex Therapeutics Price Performance

The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -7.71 and a beta of 1.33. The firm's fifty day moving average price is $19.80 and its two-hundred day moving average price is $21.60.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

Large investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its stake in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 2,933 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth about $81,000. AlphaQuest LLC increased its position in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter worth about $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.